Novel therapy using thermogel prevents retinal scarring
July 5th 2022A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.
Read More
LIGHTSITE III trial data demonstrates improvement in vision in intermediate dry AMD
June 23rd 2022LumiThera Inc. noted that the trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.
Read More
Bausch + Lomb receives permanent J-Code for triamcinolone acetonide injectable suspension
June 21st 2022The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.
Read More
Study: Investigators make key discovery in AMD
June 6th 2022According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.
Read More
Health Canada approves faricimab injection for the treatment of wet AMD, DME
June 1st 2022Faricimab is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.
Read More
GA therapy endpoints: Should tissue preservation be considered?
May 27th 2022As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.
Watch